Member Info for inanaco

nothing we are missing otherwise we would not have made it to the last 10 out of 140 .. its possible that scancell has actually gone to far on its own ... i did say this that the Modi1/2/3 are all interlinked so rather than it being fresh research to develop out we could be classed as partially proven ...

anyway we can speculate till the cows come home .. as it stands no grant from CRUK so time to move on with existing projects, unless another source of funding is coming

as at this moment .. SCLP are not in the frame ..

Agree taking on staff to cover the current programs .. indicates movement to the positive ...

well that's iced the Modi3 program then ... nothing's changed ...

last 30 mins ... before the next RNS ... quite an expectation eh ! it's the biggest Pot of cash that Scancell has been able to access since it floated ... targeted at an area where we have considerable experience

it's like entering the earth's atmosphere ... at midnight radio blackout .... does the 3 min window reflect anything ?

we are not Apollo 13 ...

"""""""""" even though surprising targets may be lurking in these tumors.""""""""""""

stress induced Antigens .......... welcome to our world,

https://scopeblog.stanford.edu/2017/03/30/previously-elusive-targets-for-cancer-immunotherapy-identified/

Picking the antigens that you'll use to treat a patient is not trivial. Here we built a platform to identify neoantigens directly in patients. This is one of the biggest studies of its kind, and it highlights the fact that most abnormal proteins found in cancer cells are unlikely to be targets for T cells. This suggests that devising cancer immunotherapies from mutations alone is unlikely to be as straightforward as many people have thought, even though surprising targets may be lurking in these tumors.

Antigens and epitopes .........

this is why the industry has such difficulty in finding them .........

Out of 36,500 antigens bound by the patients' MHC, the researchers identified just 52 that were specifically associated with the cancer cells. Remarkably, each of these 52 peptides were derived from just one protein -- the immunoglobulin receptor on the surface of the cancer cells. This was particularly surprising due to the fact that the researchers, using a separate technique, had identified between 13 and 175 cancer-specific mutations, or putative targets, per patient.

The implications are striking. Most abnormal cancer proteins, it seems, are not effective recognition targets at all. Instead, only the select few that are displayed by the cancer cell MHC are likely to be prime targets for immunotherapy. And although this study specifically studied mantle cell lymphoma, there's reason to expect that the immune response to other cancers might be similar, the researchers believe. If so, it's imperative to identify effective targets before beginning immunotherapy.

The moditope suite ... works !!

i don't worry about it like you chap .. we are at the ends of the spectrum in that regard

you bought at 10p last year .. Ruck .. its coming back to you

don't worry so much

You are at it again ....... i never undervalued SCIB1 .. what i said was, it underpins the SP at this level ... on its own

in other words everything else is a bonus

and we have not commercialised it yet as we are about to test it in the best way possible with the current standard of care PD-1

its like have a base model 3 series BMW and cancelling the order and going for an M3 instead

for some reason you have gone from Mr Expert at valuing Pharma that only make 5% profits ....To some sort of Business angel who can identify why scancell has not yet commercialised SCIB1

Your track record is abysmal and Ivy continues to back you up while at the same time undermining you as his record is just as bad.

well its £20m of research paid for taking modi3 into trial .... in the hardest to treat cancers .. so it secures non dilutive funding for this project for a few years

But the biggest gain as an investor is the Peer Review of the Science of the program ... thing is you cannot peer review what has not been developed ... what you are doing is peer reviewing how you get there ....
so the backdrop is

TCR modi1 collaboration
Modi1 vaccine
Modi 2 pre-clinical evaluation based around Homocitrulline

So if all goes well .. Thumbs up to Immunobody and Moditope by CRUK ..

that's serious pedigree

and that in my mind puts to bed any questioning of the science as a negative ... regarding Moditope

with the lead program SCIB1/Keytruda with its impressive data as an adjuvant therapy with identifiable destruction of lungs mets of melanoma should be able to support the value behind the SP at this level on its own

Tick Tock

9.9 gone though on nex

Ivy ....

if you actually read what is written ... rather than trying to support Ruck with your half cocked interpretation then what you have just posted conflicts with itself

why would you sell product direct and get paid by Royalties ..?

a royalty on sales has no costs attributed against it other than cashing the cheque

if scancell license with a 10% royalty Scancells receives 10% of sales ..regardless of the sellers costs ..

so 95% of the royalty paid is easy enough to achieve .. which is profit after administration .. costs

Plenty for all ......

Rats

as i have already explained as of today Scancells business model is based around lump sums, stage payments and royalties ,,,

only the royalty element is "" linked""" to turnover

so again i will point out that Ruck analysis of 5% on Scancells turnover is just wrong as that element could be very high maybe more like 95% as little management is involved in collecting royalties

and just to be clear ... the first set of numbers i took from the BBC headline figures

https://www.bbc.co.uk/news/business-28212223

so basically you pick a number then find the year that the profit is nearest to your guess ..... LOL

5 % .......... never happened

who mentioned the 2017 accounts ?